United States-Abraham Accords Cooperation and Security Act of 2025
Summary
What This Bill Does
The U.S.-Abraham Accords Cooperation and Security Act establishes a Food and Drug Administration office located in an Abraham Accords country. Within two years, the FDA Commissioner must select the location after consulting partner governments and U.S. diplomatic and security personnel, appoint a director, and assign FDA staff. The office provides technical assistance to regulatory partners in Abraham Accords countries on oversight and convergence for FDA-regulated products, including good manufacturing and clinical practices. The bill uses FDA presence abroad to build regulatory capacity, align standards, and support safer trade in foods, drugs, devices, biologics, cosmetics, and other regulated products.
Who Benefits and How
Abraham Accords regulatory authorities benefit from direct FDA technical assistance and standards-convergence support. Medical product manufacturers benefit if more aligned regulatory practices reduce uncertainty across participating markets. U.S. food and drug exporters benefit from stronger partner-country regulatory capacity and more predictable oversight. FDA international programs benefit from a dedicated regional office and director for Abraham Accords cooperation.
Who Bears the Burden and How
The Food and Drug Administration must select a location, appoint a director, assign staff, and operate the overseas office. U.S. diplomatic security personnel must advise on location and security risks. Partner-country regulators must coordinate with FDA staff and adapt technical-assistance work to local law. Federal taxpayers bear the cost of staffing and maintaining the new FDA office.
Key Provisions
- Creates an FDA Abraham Accords Office headed by a director.
- Requires the office to be located in an Abraham Accords country selected within two years.
- Requires consultation with partner governments and U.S. diplomatic and security personnel.
- Provides technical assistance on oversight and regulatory convergence for FDA-regulated products.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Creates an FDA Abraham Accords Office in an Abraham Accords country to provide technical assistance and regulatory-convergence support to partner-country authorities on FDA-regulated products.
Key Policy Areas
Food and Drug Administration, Foreign Affairs, Trade
Primary Purpose
Creates an FDA Abraham Accords Office in an Abraham Accords country to provide technical assistance and regulatory-convergence support to partner-country authorities on FDA-regulated products.
Policy Domains
Resolution provisions
Identified Gains
- Abraham Accords regulatory authorities
- Medical product manufacturers
- U.S. food and drug exporters
- FDA international programs
Identified Costs
- Food and Drug Administration
- U.S. diplomatic security personnel
- Partner-country regulators
- Federal taxpayers
Sponsors
Legislative Progress
In CommitteeMrs. Harshbarger (for herself, Mr. Vargas, Mr. Weber of Texas, …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Abraham Accords regulatory authorities, Food and Drug Administration
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology